Alector (ALEC) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Alector (ALEC) over the past year, gaining 4.1% versus a loss of 34.4%. Over five years, IFRX leads with a -38.1% price change compared with -91.3% for ALEC. Alector is the larger company by market cap ($225.5 million vs $225.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALEC | IFRX |
|---|---|---|
| Share price | $2.02 | $1.53 |
| Market cap | $225.55M | $225.47M |
| 1-day change | +5.21% | -1.92% |
| YTD return | +29.49% | +51.49% |
| 1-year return | -34.42% | +4.08% |
| 5-year return | -91.33% | -38.06% |
| EPS (TTM) | $-1.09 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.40 | $2.95 |
| 52-week low | $1.09 | $0.798 |
| Distance from 52-week high | -40.59% | -48.12% |
| Analyst consensus | hold | none |
| Avg. price target upside | +63.37% | +401.96% |
| Average volume | 2.86M | 798.72K |
| Shares outstanding | 111.66M | 147.37M |
| Employees | 103 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed ALEC by 38.5 percentage points over the past year.
About Alector
ALEC stock →Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 103 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ALEC vs IFRX FAQ
Which is bigger, Alector or InflaRx N.V.?
Alector (ALEC) is larger, with a market capitalization of $225.55M compared with $225.47M for InflaRx N.V. (IFRX).
Which stock has performed better over the past year, ALEC or IFRX?
IFRX returned +4.08% over the past 12 months, compared with -34.42% for ALEC (price return, excluding dividends). Past performance does not predict future results.
Are Alector and InflaRx N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Alector and Biotechnology: Pharmaceutical Preparations for InflaRx N.V..